Dr. Agarwal’s Health Care Limited announced a schedule of analyst and investor meetings set for mid-September 2026. The company will engage with stakeholders through group and one-on-one sessions across two major forums.

The engagements are part of the company's ongoing efforts to maintain transparent communication with the investment community. Officials from Dr Agarwal's will participate in physical meetings organized by leading financial institutions.

Meeting Schedule

The company has confirmed participation in two specific events over three days. Both forums will facilitate direct interaction between management and market participants.

Regulatory Compliance

The disclosures are made pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company emphasized strict adherence to its Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information.

Management stated that no unpublished price-sensitive information or forward-looking statements will be disclosed during these conferences. This ensures equal access to information for all investors.

Thanikainathan Arumugam, Company Secretary and Compliance Officer, issued the communication on August 25, 2026. The schedule is subject to change based on exigencies involving analysts, investors, or the company.

Catalyst Trusteeship Limited disclosed the creation of a pledge over 7,538,303 equity shares of Dr. Agarwal's Health Care Limited , representing 2.38% of the issued and paid-up share capital.

The encumbrance was created on August 21, 2026, in favour of Catalyst Trusteeship Limited acting as the onshore security agent for lenders to Hyperion Investments Pte. Ltd.

Pledge Dynamics

The newly pledged shares formed part of a larger block released earlier in August. On August 11, 2026, a pledge over 31,698,303 equity shares was released, with disclosure made on August 13, 2026, under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Prior to this release, Hyperion Investments had pledged 73,193,988 equity shares under a facility agreement dated March 26, 2024, for a facility aggregating up to USD 100,000,000. The initial disclosure under Regulation 29(1) was made on February 6, 2025.

Current Holding Status

Following the recent creation of encumbrance, the total shares held by the acquirer in the nature of encumbrance stand at 49,033,988. This represents 15.47% of the total share capital and 15.36% of the diluted share capital.

The target company’s total voting capital remains unchanged at 316,983,028 fully paid-up equity shares of INR 1/- each. The total diluted share capital stands at 319,262,876 shares.

What the Numbers Show

The data reveals a net reduction in pledged collateral despite the fresh encumbrance. While 7.54 million shares were newly pledged on August 21, this follows the release of 31.70 million shares just ten days prior. The net effect is a decrease of approximately 24.16 million shares from the peak pledge level of 73.19 million shares established in March 2024. This suggests active management of security cover against the USD 100 million facility rather than an accumulation of new debt exposure.